Evidence map›Paper›PMID 40247384›Full record

Trial reportItalian journal of pediatrics2025

Efficacy of treating Helicobacter pylori infection on seizure frequency in children with drug-resistant idiopathic generalized epilepsy: a randomized controlled trial.

Mostafa Ashry Mohamed, Ekram A Mahmoud, Mina S Basily, Montaser M Mohamed, Omar A A Ahmed, Elsayed Abdelkreem

Registry-linked trialAbstract readClinical Trial, Phase IIClinical Trial, Phase IIIRandomized Controlled Trial
In one paragraph

Trial report in Italian journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05297695 (Effect of Treating Helicobacter Pylori Infection on Seizure Frequency in Children With Drug-Resistant Idiopathic Generalized Epilepsy), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05297695 phase2 / phase3completednot on this map

Effect of Treating Helicobacter Pylori Infection on Seizure Frequency in Children With Drug-Resistant Idiopathic Generalized Epilepsy

TypeinterventionalSponsorSohag UniversityRan2022 to 2023Enrolled126ConditionsEpilepsy, Generalized, Helicobacter Pylori InfectionArmsTriple therapy for H. pylori infection
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mostafa Ashry MohamedDepartment of Pediatrics, Faculty of Medicine, Sohag University, Nasser City, Sohag, Egypt.
Ekram A MahmoudDepartment of Medical Microbiology and Immunology, Faculty of Medicine, Sohag University, Nasser City, Sohag, Egypt.
Mina S BasilyDepartment of Pediatrics, Faculty of Medicine, Sohag University, Nasser City, Sohag, Egypt.
Montaser M MohamedDepartment of Pediatrics, Faculty of Medicine, Sohag University, Nasser City, Sohag, Egypt.
Omar A A AhmedDepartment of Pediatrics, Faculty of Medicine, Sohag University, Nasser City, Sohag, Egypt.
Elsayed AbdelkreemDepartment of Pediatrics, Faculty of Medicine, Sohag University, Nasser City, Sohag, Egypt. d.elsayedmohammed@med.sohag.edu.eg.ORCID http://orcid.org/0000-0002-8976-2989

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHelicobacter pylori (H. pylori) causes chronic infection in more than half of the population worldwide. Accumulating body of evidence indicates the possible role of H. Pylori infection in extra-intestinal health problems, including epilepsy. This study aims to investigate the efficacy of treating H. pylori infection on seizure frequency among children with drug-resistant idiopathic generalized epilepsy (IGE).

methodsA parallel, two-arm, open-label, randomized controlled trial was conducted on 126 children with drug-resistant IGE and positive H. pylori stool antigen test who were randomly assigned to study and comparison groups in 1.2:1 ratio. Only the study group received H. pylori eradication therapy (esomeprazole, amoxicillin, and clarithromycin) for two weeks. The primary outcome was seizure improvement (≥ 50% seizure frequency reduction compared with baseline) after 2.5 months. Secondary outcomes were occurrence of status epilepticus, escalation of antiseizure medication (ASMs), and adverse effects. Outcomes between the two groups were compared using Chi-square/Fisher exact tests on an intention-to-treat principle. Logistic regression analysis was performed to investigate possible effects of baseline variables on primary outcome.

resultsSeizure improvement occurred in 23 (33%) children in the study group compared with seven (12%) children in the comparison group (Risk ratio [RR] 2.7, 95% confidence interval [CI]: 1.3-5.9; p 0.006). The study group had lower occurrence of status epilepticus (2.9% vs. 14%; RR 0.21, 95%CI: 0.05-0.93; p 0.042) and lesser need for ASMs escalation (4.4% vs. 19.3%; RR 0.23, 95%CI: 0.07-0.77; p 0.010). Adverse effects were more frequent among subjects in the study group, including nausea (15.9% vs. 10.5%) vomiting (8.7% vs. 3.5%), diarrhea (11.6% vs. 5.3%), and skin rash (4.4% vs. 1.8%), but the differences were not statistically significant (p > 0.05). None of baseline participants' variables was significantly associated with the primary outcome.

conclusionTreating H. pylori infection may improve seizure control in children with drug-resistant IGE, but further studies are warranted to confirm our findings and explore mechanisms behind seizure improvement following H. pylori eradication therapy.

trial registrationRegistered on www. CLINICALTRIALS: gov (identifier: NCT05297695) on 17 March 2022. https://clinicaltrials.gov/study/NCT05297695 .

Indexed as

Anti-Bacterial AgentsDrug Resistant EpilepsyEpilepsy, GeneralizedHelicobacter InfectionsHelicobacter pyloriSeizuresAdolescentAmoxicillinChildChild, PreschoolClarithromycinDrug Therapy, CombinationFemaleHumansMaleTreatment OutcomeAmoxicillinAnti-Bacterial AgentsClarithromycinChildrenConvulsionDrug-resistant epilepsyHelicobacter pyloriSeizures

Identifiers

PMID40247384
PMCPMC12004564

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.